Cytomos is the first TechBio company finally enabling game-changing decisions through its patented real-time AuraCyt™ platform agnostically translating complex cell data into actionable insights to materially improve Cell Line Development, CAR-T manufacturing efficacy & iPSC productivity. The technology closely monitors a broad range of individual cell features simultaneously and collects data on intrinsic cellular properties in real-time, delivering unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications.
AuraCyt™ has been brought to market via R&D benchtop solution (Celledonia™) to accelerate access for their early tech adopters: the world’s best in class C(D)MOs & global biopharma clients and their leading bioreactor platform providers.